BACKGROUND: It is increasingly evident that there is a close connection between the generation of cutaneous inflammatory cytokines and elevated neuropeptide signaling in complex regional pain syndrome (CRPS) patients. Previously, we observed in the rat tibia fracture model of CRPS that activation of caspase-1 containing NALP1 inflammasomes was required for interleukin (IL)-1␤ production in keratinocytes, and that administration of an IL-1 receptor antagonist (anakinra) reduced the fracture-induced hindpaw mechanical allodynia. We therefore hypothesized that neuropeptides lead to nociceptive sensitization through activation of the skin's innate immune system by enhancing inflammasome expression and caspase-1 activity. METHODS: We determined whether the neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP) require IL-1␤ to support nociceptive sensitization when injected into mouse hindpaw skin by testing mechanical allodynia. We then investigated whether these neuropeptides could stimulate production of IL-1␤ in a keratinocyte cell line (REKs), and could increase the expression of inflammasome component proteins including NALP1 and caspase-1. Finally, we determined whether neuropeptide-stimulated IL-1␤ production required activation of caspase-1 and cathepsin B. RESULTS: Intraplantar injections of SP and CGRP lead to allodynia in mouse hindpaws but CGRP was approximately 10-fold less potent in causing this response. Moreover, systemic administration of the IL-1 receptor (IL-1R) antagonist anakinra prevented sensitization after neuropeptide injection. Also, mouse skin keratinocytes express IL-1R, which is up-regulated after local neuropeptide application. In vitro data demonstrated that both SP and CGRP increased IL-1␤ gene and protein expression in REKs in a dose-dependent manner. Furthermore, SP time-and dose-dependently up-regulated NALP1 and caspase-1 mRNA and protein levels in REKs. In contrast, CGRP time-and dose-dependently enhanced NALP1 and caspase-1 mRNA levels without causing a significant change in NALP1 or caspase-1 protein expression in REKs. Inhibition of caspase-1 activity using the selective inhibitor Ac-YVAD-CHO reduced SP and, less effectively, CGRP induced increases in IL-1␤ production in REK cells. The selective cathepsin B inhibitor CA-74Me inhibited neuropeptide induced IL-1␤ production in REKs as well. CONCLUSIONS: Collectively, these results demonstrate that neuropeptides induce nociceptive sensitization by enhancing IL-1 ␤ production in keratinocytes. Neuropeptides rely on both caspase-1 and cathepsin B for this enhanced production. Neurocutaneous signaling involving neuropeptide activation of the innate immunity may contribute to pain in CRPS patients. (Anesth Analg 2011;113:175-83) From the *Veterans Affairs Palo Alto Health Care System, Palo Alto,
P eripheral mechanisms supporting chronic pain remain enigmatic. Although we have an advanced understanding of neuroplastic events in spinal cord and brain tissue that accompany and support many types of chronic pain, peripheral mechanisms have not enjoyed the same degree of attention. Studies on complex regional pain syndrome (CRPS) indicate that this condition requires the generation of inflammatory mediators such as cytokines and the activation of neuropeptide expressing small afferent nerve fibers in the joints and skin. 1, 2 Peripheral neuropeptide release is required for cytokine production and subsequent nociceptive sensitization after incision as well. 3 Thus, interest in the mechanisms linking peripheral neural activity to inflammation and sensitization has increased as our understanding of neuroinflammation has grown.
Focusing on CRPS, it appears that dysregulated innate immunity characterizes this syndrome. For example, measurements of the levels of cytokines in venous blood , as well as the analysis of fluid from suction blisters created on the skin of CRPS-affected extremities showed elevated levels of several cytokines. 4, 5 Likewise, elevated levels of both substance P (SP) and calcitonin gene-related peptide (CGRP) have been found in venous blood from the extremities of CRPS patients. 5, 6 A connection between the release of neuropeptides and CRPS has been suggested by clinical studies demonstrating abnormal plasma extravasation in the skin of CRPS patients after cutaneous SP administration. 7 Also, observations of abnormal responses to cutaneous capsaicin administration causing afferent fiber neuropeptide release in a human model of CRPS highlight this connection. 8 In a recently developed rat tibia fracture/cast immobilization model of CRPS, the human findings were greatly extended. Using this model, it was observed that SP signaling through its cognate neurokinin 1 receptor was required for the nociceptive sensitization characteristic of CRPS and that both SP and CGRP were up-regulated in primary afferent neurons. 9, 10 Similarly, the continuous administration of the interleukin (IL)-1 receptor blocker anakinra reduced both the nociceptive sensitization in these animals and evidence of peripheral inflammation. 11 Caspase-1 enzyme cleaves pro-IL-1␤ to its mature form IL-1␤, which is required for nociceptive sensitization. 12 It is also the active enzymatic component of the NALP1 inflammasome. This structure consists of 3 proteins, NALP1, an adaptor known as apoptosis-associated specklike protein containing CARD, and caspase-1. 13 Additionally, a recent report showed that NALP1 inflammasomes containing caspase-1 are activated in keratinocytes after fracture and immobilization of rat hindlimbs. 12 Lastly, cathepsin B contributes to the maturation of pro-IL-1␤ by mechanisms including direct cleavage of pro-IL-1␤ and by participating in the activation of inflammasomes including the NALP1 inflammasome. 14 -17 In this report we attempt to address directly the question of whether the neuropeptides SP and CGRP require the production of IL-1␤ to support nociceptive sensitization when injected into rodent hindpaw skin. In complementary experiments we sought to determine whether these neuropeptides could stimulate the production of IL-1␤ in a keratinocyte cell line, whether any such IL-1␤ production required caspase-1 or cathepsin B activation, and whether these changes were accompanied by the increased expression of components of the NALP1 inflammasome.
METHODS Animals
These experiments were approved by our Institutional Animal Care and Use Committee. All animals were treated in accordance with the guideline of the National Institutes of Health Guide for the Care and Use of Laboratory Animals and followed the guidelines of the International Association for the Study of Pain. Eight-to ten-week-old male C57BL/6 mice were used in all experiments. They were housed 5 to a cage in standard isolator cages maintained at 22°Ϯ 1°C with 14-hour light and 10-hour dark cycles. The animals were allowed free access to food and drinking water.
Drug Treatments
The C57BL/6 mice were treated once with IL-1␤ receptor antagonist anakinra (Amgen, Thousand Oaks, CA) at a dose of 120 mg/kg i.p. or saline 1 hour before the SP or CGRP administration. The anakinra dose was based on previous studies. 12, 18 Intraplantar injection of saline, SP (300 ng and 1000 ng, 15 L of saline), or CGRP (3 g and 10 g, 15 L of saline) into the hindpaw were made before nociceptive testing.
Hindpaw Nociception
The hindpaw mechanical allodynia was measured using nylon von Frey filaments according to the "up-down" algorithm described by Chaplan et al., 19 as we have used previously. 20 -22 Briefly, mice were placed in a clear plastic cylinder (10 cm in diameter and 40 cm in height) on a wire mesh platform and allowed to acclimate for 15 minutes. Fibers of sequentially increasing stiffness (0.2 to 2.0 g; 7 fibers) were applied to the center of the hindpaw plantar skin just distal to the first set of foot pads. Four fibers were applied after the first one causing a withdrawal response, to estimate withdraw threshold.
Cell Culture
The epidermal keratinocyte (REK) cell line was generously provided by Dr. Howard Baden (Massachussetts General Hospital, Boston, MA) and grown as described previously. [23] [24] [25] In brief, cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, CA), supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, 0.4 g/mL hydrocortisone, and 0.75 mM aminoguanidine. On reaching approximately 90% confluence, the cells were starved with the above culture medium supplemented with only 1% FBS overnight. Cells were then washed twice with fresh DMEM before addition of SP (Sigma Chemical Co., St. Louis, MO), CGRP (Sigma), or saline vehicle. At least 5 culture dishes were used for each time point, treatment condition, and experiment.
Quantitative Real-Time PCR
Total RNA from the REKs was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA). The cDNA (20 L final volume) was synthesized from 1 g RNA using iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA). Real-time polymerase chain reactions (PCRs) were conducted using the SYBR Green PCR master mix (Applied Biosystems, Foster City, CA). Real-time PCR amplification of IL-1R, NAPL1, caspase-1, and 18S was performed on the ABI 7900HT sequencing detection system. To validate the primer sets used, we performed dissociation curves to document single product formation, and agarose gel analysis was conducted to confirm the size. The data were analyzed by the comparative C T (cycle threshold) method, as described in the manufacturer's manual. All results were confirmed by repeating the experiment 3 times.
IL-1␤ ELISA
On reaching confluence, cells were treated with neuropeptides SP and CGRP (final concentrations up to 10 Ϫ7 M) with and without addition of selective caspase-1 inhibitor, Ac-YVAD-CHO (Cayman Chemical, Ann Arbor, MI), or a selective cathepsin B inhibitor, CA-74Me (EMD Biosciences, San Diego, CA) for 24 hours. The cell culture supernatant and cell lysate were then collected at the indicated time.
The IL-1␤ protein level in the undiluted cell culture supernatant was measured by an R&D System EIA kit (Minneapolis, MN) according to the manufacturer's protocol. Protein content in the culture medium was determined using a Coomassie Blue Protein Assay Kit (Pierce, Rockford, IL). The results of this assay were confirmed by repeating the experiment twice.
Western Blot
Cultured rat keratinocytes were harvested and homogenized in Tris buffer pH 6.8 with freshly added protease inhibitors, ␤-mercaptoethanol, and glycerol. The homogenate was centrifuged at 13,000 g for 15 minutes at 4°C. Equal amounts of protein were size fractionated by 10% SDS-PAGE gel electrophoresis and transferred onto a polyvinylidene difluorided membrane, which were then blocked overnight and incubated with primary rabbit anti NAPL1 (1:400; Cell Signaling Technology, Danvers, MA) or rabbit anticaspase-1 antibody (1:200; BioVision Research, Mountain View, CA). After washing, the blots were incubated with horseradish peroxidase conjugated antirabbit antibody (Santa Cruz Biotechnology, Santa Cruz, CA) (diluted in 1:5000) for 1 hour at room temperature. The membrane was then washed again and exposed to film after chemiluminescence reagent treatment with the ECL plus (Amersham, Piscataway, NJ). Bands were quantified using densitometry of digitalized images. Each blot was then stripped and reprobed with anti-␤ actin antibodies, thus allowing normalization of expression among samples. The results of this assay were confirmed by repeating the experiment 3 times.
Immunohistochemical Analysis
The immunohistochemical analysis of mouse paw skin was done according to previously published methods. 20, 26 The primary antibodies used were interleukin-1 (IL-R1) receptor 1:50 (Abcam Inc., Cambridge, MA) and keratin1:50 (Thermo Scientific Inc., Waltham, MA). Fluoresceinconjugated secondary antibodies against the primary antibodies were applied in 1:150 concentrations (Jackson ImmunoResearch Laboratories, West Grove, PA, & Vector Laboratories Inc., Burlingame, CA). Confocal laser-scanning microscopy was performed using Zeiss LSM 510 and LSM 510 META Laser Scanning Microscopes (Thornwood, NY). Control experiments included incubation of slices in primary and secondary antibody-free solutions, both of which led to low-intensity nonspecific staining patterns in preliminary experiments.
Statistical Analysis
To compare the time course effects of treatments and individual groups for the behavior studies testing mechanical allodynia, a 2-way analysis of variance (ANOVA) (time, treatment) with repeated measures for time was performed with Bonferroni tests for multiple comparisons. Other data were analyzed by 2-way ANOVA followed by post hoc Bonferroni multiple comparisons tests. All data are presented as means Ϯ SE, and differences are considered significant at a P value Ͻ0.05 (Prism 4.0, GraphPad Software, San Diego, CA).
RESULTS

Neuropeptides SP and CGRP Cause Nociceptive Sensitization Dependent on IL-1␤ Signaling
The first hypothesis addressed was that neuropeptides released from primary afferent neurons lead to nociceptive sensitization, and that this sensitization relies upon IL-1␤ signaling. We selected a measurement approach using von Frey filaments application to hindpaw skin because it was the function of skin and superficial tissues in support of nociception that was of interest. Figure 1 shows that subcutaneous injections of SP and CGRP cause allodynia in the hindpaws of mice, though the response was delayed by several hours from the time of injection. CGRP was approximately 10-fold less potent in causing this response, and the response was more transient. Recombinant IL-1 Figure 1 . Interleukin (IL)-1␤ receptor antagonist (IL-1ra, anakinra, 120 mg/kg, i.p.) prevents the mechanical sensitization induced by intraplantar injection of various doses of substance P (SP) or calcitonin gene-related peptide (CGRP). A, SP (300 ng and 1000 ng) caused significant mechanical allodynia lasting between 1 and 6 hours, whereas the anakinra preinjected mice displayed reduced hindpaw mechanical allodynia caused by SP. B, CGRP (3 g and 10 g) caused significant mechanical allodynia between 1 and 2 hours, whereas the anakinra preinjected mice displayed reduced hindpaw mechanical allodynia induced by CGRP. Values are means Ϯ SE; n ϭ 6 mice for all experimental groups. *P Ͻ 0.05. **P Ͻ 0.01. ***P Ͻ 0.001 for differences in relation to baseline. #P Ͻ 0.05 for differences between the nonanakinra and anakinra pretreated mice that were injected with the same dose of SP or CGRP.
receptor antagonist (anakinra) was systemically administered before local application of neuropeptides in additional experiments. For SP, anakinra readily prevented sensitization caused by relatively low doses of the neuropeptide (Fig. 1A) . Anakinra also blocked CGRP-induced sensitization even at a high (10 g) dose (Fig. 1B) .
Next, determination of IL-1 receptor (IL-1R) presence and expression in the hindpaw skin was performed. Figure  2A demonstrates that the epidermal keratinocytes express IL-1R before and after neuropeptide SP application. Additionally, there is an increased IL-1R1 mRNA expression in the skin 2 hours after local SP application versus controls (Fig. 2B ).
Neuropeptides SP and CGRP Dose-and Time-Dependently Increase IL-1␤ mRNA and Protein Levels in Cell Cultures
The second hypothesis addressed was that neuropeptide stimulation of IL-1␤ production could be recapitulated in a commonly used rodent keratinocyte cell line, REK. Cultures of these cells were exposed to 10 Ϫ10 to 10 Ϫ7 M concentrations of the neuropeptides for 3 or 24 hours separately. Enhanced levels of both IL-1␤ mRNA and protein were observed in these cultures, and these effects were dose dependent ( Fig. 3) . For both neuropeptides, maximal responses occurred at approximately 10 Ϫ8 neuropeptide concentration.
Neuropeptides SP and CGRP Dose-and Time-Dependently Enhance NALP1 mRNA and Protein Levels
Because epidermal NALP-1 protein is up-regulated in the rat fracture model of CRPS, a model that depends on intact SP signaling, 12 we hypothesized that exposure of REKs to neuropeptides would lead to an up-regulation in expression of NALP1. Figure 4 shows that SP up-regulates both NALP1 mRNA and protein, with the increase in protein concentration seen at 24 hours after exposure to SP. Specifically, the short form of NALP1, which is capable of assembling with other proteins to form the NALP1 inflammasome, was increased. 27 The neuropeptide CGRP enhanced NALP1 mRNA levels without causing an increase in NALP1 protein in the cultures.
Neuropeptides SP and CGRP Dose-and Time-Dependently Enhance Caspase-1 mRNA and Protein Levels
As neuropeptides enhance IL-1␤ levels and as NALP1 protein is up-regulated by SP, we measured changes in caspase-1 levels 3 and 24 hours after beginning SP or CGRP treatment. Similar to the results for NALP1, SP and CGRP enhanced caspase-1 mRNA levels, but only SP (10 Ϫ8 M) at 24 hours caused a statistically significant increase in caspase-1 protein levels (Fig. 5 ).
Aactivation of Caspase-1 Is Required for Neuropeptide Enhancement of IL-1␤ Production
To determine whether neuropeptide-stimulated IL-1␤ production in REK cells was caspase-1 dependent, we incubated separate REK cultures with each neuropeptide at concentrations that had near-maximal efficacy, and with 2 doses of Ac-YVAD-CHO, which is a selective caspase-1 inhibitor. 28 Figure 6 displays the data showing that caspase-1 activity is in fact required for SP-induced IL-1␤ production. The effect of Ac-YVAD-CHO on CGRPinduced IL-1␤ production was less prominent at the highest dose of inhibitor used.
Cathepsin B Contributes to Neuropeptide Stimulated IL-1␤ Production
We used CA-74Me, which is a selective cathepsin B inhibitor, in the REK culture system along with SP and CGRP to determine the contribution of this pathway in the production of IL-1␤. 29 Figure 7 shows the dosedependent effect of the cathepsin B inhibitor in reducing the neuropeptide-stimulated cytokine production.
DISCUSSION
In attempting to better understand the mechanisms supporting CRPS, attention has recently shifted to the periphery, particularly to the question of how the peripheral nervous system interacts with somatic tissues. In this series of studies we examined the link between 2 specific neuropeptides expressed and released by primary afferent nerve fibers and keratinocytes, cells producing cytokines such as IL-1␤ supporting pain and neurogenic inflammation in CRPS. Our principal findings were (1) that SP and CGRP could by themselves cause nociceptive sensitization, which relied upon IL-1␤ signaling, (2) that SP and CGRP stimulate the production of IL-1␤ in a keratinocyte cell line via caspase-1-dependent and possibly caspase-1-independent mechanisms, and (3) that key components of the NALP1 inflammasome were up-regulated after exposure of cultures to SP, but not CGRP to a measurable extent. Taken as a group, our results suggest that neurocutaneous signaling mediated by the activation of the innate system of immunity by neuropeptides may contribute to the pain experienced by CRPS sufferers.
Because earlier studies demonstrated that keratinocytes might be an important target for neuropeptides in stimulating cytokine production, we then applied SP and CGRP directly to REK cultures and demonstrated an enhanced production of IL-1␤ at both the mRNA and protein levels with protein changes lagging behind those of IL-1␤ mRNA. Keratinocytes express receptors for SP (neurokinin 1) and CGRP (CRLR, RAMP1, and RAMP2), 10,30 -32 and previous reports have provided data demonstrating that epidermal and other types of epithelial cells produce IL-1␤ in response to neuropeptide stimulation. 33 Moreover, we had previously demonstrated that in vivo direct application of SP to mouse hindpaw skin results in an increased production of IL-1␤. 3 The keratinocyte culture data taken together with the skin IL-1␤ production after SP stimulation support the notion of epidermal keratinocytes participating in the neurogenic inflammation process. The presence of IL-1R on skin epidermal cells and the present finding of IL-1R antagonist anakinra blocking local SP-induced skin sensitization further support this notion. Additional studies may be required to determine the extent of involvement of other cell types (neutrophil, macrophage, etc.) in neuropeptidemediated skin sensitization; nevertheless, the present findings implicate keratinocytes as notable participants in neuropeptide-induced pain.
Further experiments using the selective caspase-1 inhibitor Ac-YVAD-CHO demonstrated that SP-and CGRPstimulated IL-1␤ production was dependent on the activation of caspase-1. Caspase-1 has a well-established ability to convert pro-IL-1␤ to its active form. 34, 35 We pursued further pharmacological experiments using a cathepsin B inhibitor because this enzyme can regulate inflammasomeassociated caspase-1 activity. 15 Moreover, cathepsin B is produced and secreted by keratinocytes. 36 The selective cathepsin B inhibitor CA-74Me potently reduced neuropeptide-stimulated IL-1␤ production. On the other hand, Ac-YVAD-CHO was somewhat less effective against CGRP-stimulated IL-1␤ production despite high concentrations of the inhibitor being used. This suggests that a caspase-1-independent IL-1␤ production mechanism might be present. Examples of such independent mechanisms include those involving cathepsin B, separate from its indirect effects on caspase-1 activity, and direct effects of matrix metalloproteinase to cleave pro-IL-1␤ to its active mature form. 37, 38 Additional data from our experiments demonstrating a lack of effect at the protein expression level for NALP1 and caspase-1 when CGRP was added to the cultures are also consistent with a possible inflammasome-independent pathway for CGRP-stimulated IL-1␤ production.
Much recent attention has been focused on the biology of inflammasomes, multiprotein complexes that are part of the innate system of immunity. 39 Though present in many cell types, inflammasomes have been studied in some detail in epithelial cells. Dysfunction of these structures leads to a number of diseases including Muckle-Wells syndrome, vitiligo, and other conditions characterized by dysregulated immunity. 40, 41 There are at least 3 distinct inflammasomes including the NALP1, NALP3, and IPAF varieties, though the molecular biology of NALP proteins in humans and other species suggests that many more types of NALP inflammasomes may form. 42 Our work focused on the NALP1 inflammasome because it was implicated in supporting nociceptive sensitization and the generation of IL-1␤ in the rat tibial fracture model of CRPS. 12 To this point, relatively few specific molecules were known to activate the NALP1 inflammasome, though muramyl dipeptide (MDP) and anthrax toxin promote the NALP1mediated caspase-1 activation. 43 For at least one other inflammasome, the NALP3 inflammasome, a cell surface receptor (P2X7) causes activation of the inflammasome and caspase activity. 44 Therefore, though it is not clear precisely how caspase-1 is being activated either in CRPS or in our keratinocyte model system, it does appear that receptormediated activation of the NALP1 inflammasome by neuropeptides is a plausible hypothesis.
Our observations support and are consistent with other observations concerning the roles for IL-1␤ in pain. This cytokine is found in increased abundance in the skin of animals 12, 27, 45 and humans 46, 47 experiencing pain from several different etiologies, including those involving inflammation. The cytokine IL-1␤ causes the sensitization of skin and other tissues by several mechanisms. The first mechanism is via direct interaction of the cytokine with IL-1 receptors expressed on neurons. Observations from Binshtok et al. indicate that certain populations of nociceptive neurons respond to IL-1␤ application in p38-dependent fashion by enhancing tetrodotoxin-resistant sodium ion currents and therefore excitability. 48 The second general peripheral pathway of IL-1␤ participation in nociception is by enhancing the production of other nociceptive mediators, including prostaglandin E2, tumor necrosis factor␣, IL-6, and nerve growth factor. 49 Treatment of animals having had tibia fracture and cast immobilization with IL-1R antagonist anakinra reduces not only the CRPS-like nociceptive sensitization, but also levels of the pronociceptive mediators IL-6, tumor necrosis factor ␣, and nerve growth factor in hindpaw skin. 12 Finally, IL-1␤ may have a feedback input on peripheral afferent neurons to augment their effects by increasing the production and release of SP. 50 Though our results indicate that neuropeptides can stimulate the production of IL-1␤, possibly via a NALP1 inflammasome-dependent pathway, it is unclear how the signaling promoting this up-regulation takes place. There is little information at present to help identify possible mechanisms, given the relative lack of study of NALP1 inflammasome activation through cell surface neurotransmitter receptors. Whatever that mechanism of activation, the linking of the peripheral nervous system with the innate system of immunity represents an important advancement in our understanding of neurogenic inflammation, and neurosomatic communication in general. Eventually, it may be possible to control pain and other problematic consequences of inflammation by selectively regulating such signaling pathways.
